Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:CPRXNASDAQ:CRNXNASDAQ:HCM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$8.92+3.6%$8.44$3.63▼$14.44$685.54M0.681.20 million shs759,011 shsCPRXCatalyst Pharmaceuticals$23.22-1.9%$23.91$14.75▼$26.58$2.87B0.721.13 million shs1.12 million shsCRNXCrinetics Pharmaceuticals$30.85-1.1%$31.29$24.10▼$62.53$2.97B0.28845,717 shs539,130 shsHCMHUTCHMED$15.71-6.4%$14.51$11.51▼$21.50$2.95B0.5299,951 shs65,418 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+3.60%+9.85%+7.21%-9.35%+139.14%CPRXCatalyst Pharmaceuticals-1.90%-11.74%-4.72%+2.74%+54.80%CRNXCrinetics Pharmaceuticals-1.12%-6.74%-1.25%-11.02%-31.00%HCMHUTCHMED-6.43%-6.71%+17.33%-2.90%-12.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.7471 of 5 stars3.70.00.04.72.70.80.6CPRXCatalyst Pharmaceuticals4.7735 of 5 stars3.62.00.03.93.23.32.5CRNXCrinetics Pharmaceuticals3.3785 of 5 stars3.50.00.03.72.12.50.0HCMHUTCHMED1.3162 of 5 stars2.02.00.00.02.10.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00393.27% UpsideCPRXCatalyst Pharmaceuticals 3.25Buy$32.8341.40% UpsideCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56141.67% UpsideHCMHUTCHMED 2.00Hold$19.0020.94% UpsideCurrent Analyst Ratings BreakdownLatest AVXL, HCM, CRNX, and CPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/25/2025CRNXCrinetics PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ACPRXCatalyst Pharmaceuticals$491.73M5.76$2.41 per share9.62$6.10 per share3.81CRNXCrinetics Pharmaceuticals$1.04M2,777.39N/AN/A$14.29 per share2.16HCMHUTCHMED$630.20M4.35$0.27 per share58.84$4.43 per share3.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-40.93%-36.38%8/5/2025 (Estimated)CPRXCatalyst Pharmaceuticals$163.89M$1.5714.7910.900.9636.91%42.45%36.59%8/6/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0010.76N/AN/AN/AN/A6/18/2025 (Estimated)Latest AVXL, HCM, CRNX, and CPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A9.459.45CPRXCatalyst PharmaceuticalsN/A5.114.92CRNXCrinetics PharmaceuticalsN/A16.3916.38HCMHUTCHMED0.072.812.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%CPRXCatalyst Pharmaceuticals79.22%CRNXCrinetics Pharmaceuticals98.51%HCMHUTCHMED8.82%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.00%CPRXCatalyst Pharmaceuticals10.40%CRNXCrinetics Pharmaceuticals6.00%HCMHUTCHMED3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.98 millionOptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableCRNXCrinetics Pharmaceuticals21093.63 million88.01 millionOptionableHCMHUTCHMED1,811174.32 million168.05 millionNot OptionableAVXL, HCM, CRNX, and CPRX HeadlinesRecent News About These CompaniesHUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?June 17 at 12:43 PM | marketbeat.comHUTCHMED (NASDAQ:HCM) Lowered to Buy Rating by Wall Street ZenJune 15 at 3:43 AM | americanbankingnews.comHUTCHMED (NASDAQ:HCM) Downgraded to "Buy" Rating by Wall Street ZenJune 14, 2025 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy?June 12, 2025 | marketbeat.comHutchmed introduces new share options and LTIP awardsJune 11, 2025 | uk.investing.comHUTCHMED Grants Share Options and LTIP Awards to Boost Talent RetentionJune 10, 2025 | tipranks.comHUTCHMED (NASDAQ:HCM) Rating Increased to Strong-Buy at Wall Street ZenJune 9, 2025 | americanbankingnews.comHUTCHMED (NASDAQ:HCM) Upgraded by Wall Street Zen to "Strong-Buy" RatingJune 7, 2025 | marketbeat.comWall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?June 5, 2025 | zacks.comChina accepts NDA for sintilimab and fruquintinib combo in kidney cancerJune 5, 2025 | msn.comInnovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | prnewswire.comHUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell CarcinomaJune 4, 2025 | globenewswire.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Still a Buy?June 3, 2025 | marketbeat.comHUTCHMED’s SACHI Phase III Study Shows Promising Results for Lung Cancer TreatmentJune 1, 2025 | tipranks.comHUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual MeetingJune 1, 2025 | globenewswire.comMillennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)June 1, 2025 | marketbeat.comTrinity Delta Estimates HUTCHMED FY2025 EarningsMay 31, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 27, 2025 | marketbeat.comBNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM)May 26, 2025 | marketbeat.comHUTCHMED to Present Promising Oncology Data at 2025 ASCO MeetingMay 22, 2025 | tipranks.comHUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual MeetingMay 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVXL, HCM, CRNX, and CPRX Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$8.92 +0.31 (+3.60%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$8.75 -0.17 (-1.91%) As of 05:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Catalyst Pharmaceuticals NASDAQ:CPRX$23.22 -0.45 (-1.90%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$23.24 +0.03 (+0.11%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Crinetics Pharmaceuticals NASDAQ:CRNX$30.85 -0.35 (-1.12%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$30.84 -0.01 (-0.03%) As of 06/17/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.HUTCHMED NASDAQ:HCM$15.71 -1.08 (-6.43%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$15.68 -0.03 (-0.18%) As of 06/17/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
